- WHATS NEW?
- Targeting adolescents for lipid intervention should be a priority
- Niacin restores vasoprotective effects of HDL in type 2 diabetes
- Low HDL-C is common in high-risk patients despite statin therapy
- Insights from VOYAGER on statin-induced HDL response
- rHDL attenuates platelet hyperreactivity in type 2 diabetics
- Combined analysis of HATS, FATS and AFREGS highlights importance of targeting HDL-C in metabolic syndrome
CETP and mortality: Expert Analysis
Latest trial confirms efficacy/safety profile of CETP inhibition with dalcetrapib
CETP inhibition unlikely to be responsible for hypertensive effects of torcetrapib
NHANES: low HDL-C prevalent in adolescents
Niacin restores vasoprotective effects of HDL in type 2 diabetes
Low HDL-C is common in statin-treated high-risk patients
Insights from VOYAGER on statin-induced HDL response
rHDL attenuates platelet function in type 2 diabetes
Simplifying lipid assessment: JAMA report
Do you believe HDL populations differ in their ability to protect against the development of atherosclerosis?
High-density lipoprotein cholesterol
and cardiovascular disease risk
The HDL Forum aims to provide healthcare professionals with peer-reviewed online analysis of the latest developments in scientific research and clinical management of high-density lipoprotein (HDL) cholesterol - 'good cholesterol'.
HDL is one of the hottest topics in lipid research and cardiovascular disease prevention today. Epidemiological and observational studies have established HDL cholesterol as an important independent cardiovascular risk factor. Recent research also shows that HDL plays a key role in the prevention, or even reversal, of atherosclerosis.
The Editorial Board of HDL Forum is comprised of individuals with an international reputation for leadership in HDL research, atherosclerosis and cardiovascular disease prevention. HDL Forum provides expert commentary on key developments in all of these fields, reporting regularly
from the major international meetings to ensure up to the minute coverage.
- Latest reports on HDL Research
- Upcoming meetings and reports
- Expert commentaries in Forum
- Correspondence welcomed click here for submission details
- Register now to receive your discount on 'High Density Cholesterol: The New Target'
Members of the Editorial Board of HDL Forum are internationally known for innovative leadership in HDL research, atherosclerosis and cardiovascular disease prevention.
Professor Kerry-Anne Rye, Lead Editor of HDL Forum: Professor in the Faculty of Medicine, University of Sydney, and Associate Director and Head of the Lipid Research Group, Heart Research Institute, Sydney, Australia.
Heart Research Institute
Professor Philip Barter: Professor of Medicine, University of Sydney and Director of the Heart Research Institute, Sydney, Australia.
Heart Research Institute
Dr H Bryan Brewer: Director of Lipoprotein and Atherosclerosis Research, Cardiovascular Research Institute, MedStar Research Institute, Washington Hospital Center, Washington DC, USA.
MedStar Research Institute
Professor Alan Chait: Edwin L. Bierman Professor of Medicine, Head, Division of Metabolism, Endocrinology and Nutrition and Director of Clinical Nutrition Research Unit, University of Washington, Seattle, USA.
University of Washington, CNRU
Professor M John Chapman: Director of the Dyslipidemia and Atherosclerosis Research Unit of the National Institute of Health and Medical Research (INSERM), Piti?-Salp?tri?re Hospital, Paris, France.
Institute of Health and Medical Research
Professor John JP Kastelein: Professor of Medicine and Chairman of the Department of Vascular Medicine, Academic Medical Center of the University of Amsterdam, Strategic Chair of Genetics of Cardiovascular Disease and Director of the Atherosclerosis Research Group.
AMC
Dr Anthony Wierzbicki: Director of the Lipid Unit, Guys? and St. Thomas? NHS Foundation Trust, London UK.
Guys and St. Thomas NHS Foundation Trust
Corporate sponsor
